keyword
MENU ▼
Read by QxMD icon Read
search

liver trials cancer

keyword
https://www.readbyqxmd.com/read/29052780/immunotherapy-for-hepatocellular-carcinoma-patients-is-it-ready-for-prime-time
#1
REVIEW
Joseph M Obeid, Paul R Kunk, Victor M Zaydfudim, Timothy N Bullock, Craig L Slingluff, Osama E Rahma
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the second most common cause of cancer death worldwide. Current treatment options for patients with intermediate and advanced HCC are limited, and there is an unmet need for novel therapeutic approaches. HCC is an attractive target for immunomodulation therapy, since it arises in an inflammatory milieu due to hepatitis B and C infections and cirrhosis. However, a major barrier to the development and success of immunotherapy in patients with HCC is the liver's inherent immunosuppressive function...
October 20, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/29047142/relevance-of-liver-limited-disease-in-metastatic-colorectal-cancer-subgroup-findings-of-the-fire-3-aio-krk0306-trial
#2
Julian Walter Holch, Ingrid Ricard, Sebastian Stintzing, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling-Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, Frank Kullmann, Werner Scheithauer, Michael Scholz, Sebastian Müller, Hartmut Link, Andreas Rost, Heinz-Gert Höffkes, Markus Moehler, Reinhard Udo Lindig, Lisa Miller-Phillips, Thomas Kirchner, Andreas Jung, Jobst Christian von Einem, Dominik Paul Modest, Volker Heinemann
In metastatic colorectal cancer (mCRC), liver-limited disease (LLD) is associated with a higher chance of metastectomy leading to long-term survival. However, limited data describes the prognostic and predictive relevance of initially unresectable LLD with regard to targeted first-line therapy. The present analysis investigated the relevance of initially unresectable LLD in mCRC patients treated with targeted therapy against either the epidermal growth factor receptor (EGFR) or vascular epithelial growth factor (VEGF)...
October 19, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29043599/shenyi-capsule-plus-chemotherapy-versus-chemotherapy-for-non-small-cell-lung-cancer-a-systematic-review-of-overlapping-meta-analyses
#3
Xiu-Wei Guo, Nai-Dong Hu, Gui-Zhi Sun, Meng Li, Pei-Tong Zhang
OBJECTIVE: To assist decision-makers interpret and choose among conflicting meta-analyses, as well as to offer treatment recommendations based on current best evidence by performing a systematic review of overlapping meta-analyses regarding Shenyi Capsule (, SC) plus chemotherapy versus chemotherapy of non-small cell lung cancer (NSCLC). METHODS: A literature search was conducted to select systematic reviews comparing SC plus chemotherapy with chemotherapy for NSCLC...
October 18, 2017: Chinese Journal of Integrative Medicine
https://www.readbyqxmd.com/read/29043568/intensified-neoadjuvant-multimodal-approach-in-synchronous-liver-metastases-from-gastric-cancer-a-single-institutional-experience
#4
REVIEW
L Ceniceros, A Chopitea, F Pardo, F Rotellar, L Arbea, J J Sola, J C Subtil, B Sangro, A Benito, J L Hernández-Lizoain, J Rodríguez
BACKGROUND: Synchronous liver metastases (LM) from gastric (GC) or esophagogastric junction (EGJ) adenocarcinoma are a rare events. Several trials have evaluated the role of liver surgery in this setting, but the impact of preoperative therapy remains undetermined. METHODS: Patients with synchronous LM from GC/EGJ adenocarcinoma who achieved disease control after induction chemotherapy (ICT) and were subsequently scheduled to chemoradiotherapy (CRT) to the primary tumor and surgery assessment were retrospectively analyzed...
October 17, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29038235/rare-tumor-clinic-the-university-of-california-san-diego-moores-cancer-center-experience-with-a-precision-therapy-approach
#5
Shumei Kato, Kellie Kurasaki, Sadakatsu Ikeda, Razelle Kurzrock
BACKGROUND: Patients with rare tumors may lack approved treatments and clinical trial access. Although each rare tumor is uncommon, cumulatively they account for approximately 25% of cancers. We recently initiated a Rare Tumor Clinic that emphasized a precision medicine strategy. MATERIALS AND METHODS: We investigated the first 40 patients presenting at the Rare Tumor Clinic. Next-generation sequencing (NGS) of tissue and plasma-derived, circulating-tumor DNA (ctDNA), and protein markers were assessed...
October 16, 2017: Oncologist
https://www.readbyqxmd.com/read/29038151/obesity-and-cancer-evidence-impact-and-future-directions
#6
REVIEW
Graham A Colditz, Lindsay L Peterson
BACKGROUND: Mounting evidence, particularly from prospective epidemiologic studies but with additional support from animal models and mechanistic studies, supported conclusions in 2016 by the International Agency for Research on Cancer (IARC)(3) in their review of the preventive effects of weight control on cancer risk. CONTENT: The workgroup concluded that obesity is causally related to cancer at 13 anatomic sites (esophagus: adenocarcinoma; gastric cardia; colon and rectum; liver; gallbladder; pancreas; breast: postmenopausal; uterine endometrial; ovary; kidney: renal cell; meningioma; thyroid; and multiple myeloma)...
October 16, 2017: Clinical Chemistry
https://www.readbyqxmd.com/read/29034078/recent-advances-in-cancer-surgery-in-older-patients
#7
REVIEW
Siri Rostoft, Riccardo A Audisio
Age is the most important risk factor for the occurrence of cancer, and a declining mortality from heart disease and other non-cancer causes leaves an older population that is at high risk of developing cancer. Choosing the optimal treatment for older cancer patients may be a challenge. Firstly, older age and associated factors such as comorbidities, functional limitations, and cognitive impairment are risk factors for adverse effects of cancer treatment. Secondly, older patients are often excluded from clinical trials, and current clinical guidelines rarely address how to manage cancer in patients who have comorbidities or functional limitations...
2017: F1000Research
https://www.readbyqxmd.com/read/29030124/targeting-nitric-oxide-and-nmda-receptor-associated-pathways-in-treatment-of-high-grade-glial-tumors-hypotheses-for-nitro-memantine-and-nitrones
#8
REVIEW
Meric A Altinoz, İlhan Elmaci
Glioblastoma multiforme (GBM) is a devastating brain cancer with no curative treatment. Targeting Nitric Oxide (NO) and glutamatergic pathways may help as adjunctive treatments in GBM. NO at low doses promotes tumorigenesis, while at higher levels (above 300 nM) triggers apoptosis. Gliomas actively secrete high amounts of glutamate which activates EGR signaling and mediates degradation of peritumoral tissues via excitotoxic injury. Memantine inhibits NMDA-subtype of glutamate receptors (NMDARs) and induces autophagic death of glioma cells in vitro and blocks glioma growth in vivo...
October 10, 2017: Nitric Oxide: Biology and Chemistry
https://www.readbyqxmd.com/read/29017161/prognostic-factors-for-survival-in-patients-with-advanced-intrahepatic-cholangiocarcinoma-treated-with-gemcitabine-plus-cisplatin-as-first-line-treatment
#9
Utako Ishimoto, Shunsuke Kondo, Akihiro Ohba, Mitsuhito Sasaki, Yasunari Sakamoto, Chigusa Morizane, Hideki Ueno, Takuji Okusaka
OBJECTIVES: Intrahepatic cholangiocarcinoma (ICC) is a rare type of liver cancer. No clinically useful prognostic factors have been reported for patients with advanced ICC. In the present study, we aimed to evaluate the clinical prognostic factors of patients with advanced ICC receiving gemcitabine plus cisplatin combination therapy (GC) as standard first-line chemotherapy. METHODS: A retrospective analysis was performed of the data of patients with ICC treated at our institution from March 2011 to January 2016...
October 11, 2017: Oncology
https://www.readbyqxmd.com/read/28989978/the-therapeutic-potential-of-resveratrol-a-review-of-clinical-trials
#10
Adi Y Berman, Rachel A Motechin, Maia Y Wiesenfeld, Marina K Holz
Resveratrol is a nutraceutical with several therapeutic effects. It has been shown to mimic effects of caloric restriction, exert anti-inflammatory and anti-oxidative effects, and affect the initiation and progression of many diseases through several mechanisms. While there is a wealth of in vitro and in vivo evidence that resveratrol could be a promising therapeutic agent, clinical trials must confirm its potential. In this work, we reviewed the current clinical data available regarding the pharmacological action of resveratrol...
2017: NPJ Precis Oncol
https://www.readbyqxmd.com/read/28989253/psidium-guajava-a-single-plant-for-multiple-health-problems-of-rural-indian-population
#11
REVIEW
Poonam G Daswani, Manasi S Gholkar, Tannaz J Birdi
The rural population in India faces a number of health problems and often has to rely on local remedies. Psidium guajava Linn. (guava), a tropical plant which is used as food and medicine can be used by rural communities due to its several medicinal properties. A literature search was undertaken to gauge the rural health scenario in India and compile the available literature on guava so as to reflect its usage in the treatment of multiple health conditions prevalent in rural communities. Towards this, electronic databases such as Pubmed, Science Direct, google scholar were scanned...
July 2017: Pharmacognosy Reviews
https://www.readbyqxmd.com/read/28987770/prognostic-scores-for-sorafenib-treated-hepatocellular-carcinoma-patients-a-new-application-for-the-hepatoma-arterial-embolisation-prognostic-score
#12
J Edeline, J-F Blanc, B Campillo-Gimenez, Y-T Ma, J King, O Faluyi, J Mathurin, S Ghazi, D H Palmer, T Meyer
BACKGROUND: No prognostic classification is currently used for patients treated with systemic therapies for Hepatocellular Carcinoma (HCC). METHODS: We retrospectively analysed data from patients treated with sorafenib for HCC from five centres in France and in the United Kingdom (UK). The training set comprised data from two centres and the validation set from three. Variables independently associated with Overall Survival (OS) in the training set were used to build the SAP (Sorafenib Advanced HCC Prognosis) score...
October 4, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28975832/systemic-and-adjuvant-therapies-for-intrahepatic-cholangiocarcinoma
#13
Yun Shin Chun, Milind Javle
Intrahepatic cholangiocarcinoma represents the second most common primary liver cancer and is increasing in incidence. Most patients are diagnosed at an advanced, nonsurgical stage and only about 1 in 5 cases are surgically resectable. Despite surgery, the 5-year survival is low at only 30%. Multifocal, node- or margin-positive disease is at a higher risk of recurrence after resection. There is no level 1 evidence in support of postoperative adjuvant therapy. A recent adjuvant therapy phase III trial from the Partenariat de Recherche en Oncologie Digestive-Actions Concertées dans les Cancers Colo-Rectaux et Digestifs (PRODIGE) group reported no survival advantage with adjuvant gemcitabine and oxaliplatin therapy...
July 2017: Cancer Control: Journal of the Moffitt Cancer Center
https://www.readbyqxmd.com/read/28975829/liver-directed-therapies-for-hepatocellular-carcinoma-and-intrahepatic-cholangiocarcinoma
#14
Bela Kis, Ghassan El-Haddad, Rahul A Sheth, Nainesh S Parikh, Suvranu Ganguli, Paul B Shyn, Junsung Choi, Karen T Brown
Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC) are primary liver cancers where all or most of the tumor burden is usually confined to the liver. Therefore, locoregional liver-directed therapies can provide an opportunity to control intrahepatic disease with minimal systemic side effects. The English medical literature and clinical trials were reviewed to provide a synopsis on the available liver-directed percutaneous therapies for HCC and IHC. Locoregional liver-directed therapies provide survival benefit for patients with HCC and IHC compared to best medical treatment and have lower comorbid risks compared to surgical resection...
July 2017: Cancer Control: Journal of the Moffitt Cancer Center
https://www.readbyqxmd.com/read/28962871/challenging-cancer-targets-for-aptamer-delivery
#15
REVIEW
Vittorio de Franciscis
The extraordinary boost in the understanding of the genetic and epigenetic mechanisms underlying the development and progression of different types of cancer, is offering an unprecedented hope for the development of precise therapeutics able to interfere or replace the expression of target genes. In the last decade, the design of stable, safe and effective RNA-based therapeutics has been significantly improved increasing the number of molecules now in preclinical or in clinical trials for cancer gene therapy...
September 26, 2017: Biochimie
https://www.readbyqxmd.com/read/28958502/dacomitinib-versus-gefitinib-as-first-line-treatment-for-patients-with-egfr-mutation-positive-non-small-cell-lung-cancer-archer-1050-a-randomised-open-label-phase-3-trial
#16
Yi-Long Wu, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Fumito Tsuji, Rolf Linke, Rafael Rosell, Jesus Corral, Maria Rita Migliorino, Adam Pluzanski, Eric I Sbar, Tao Wang, Jane Liang White, Sashi Nadanaciva, Rickard Sandin, Tony S Mok
BACKGROUND: Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor. We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor gefitinib in the first-line treatment of patients with advanced EGFR-mutation-positive non-small-cell lung cancer (NSCLC). METHODS: In this international, multicentre, randomised, open-label, phase 3 study (ARCHER 1050), we enrolled adults (aged ≥18 years or ≥20 years in Japan and South Korea) with newly diagnosed advanced NSCLC and one EGFR mutation (exon 19 deletion or Leu858Arg) at 71 academic medical centres and university hospitals in seven countries or special administrative regions...
September 25, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28954418/adherence-to-mediterranean-diet-and-risk-of-cancer-an-updated-systematic-review-and-meta-analysis
#17
REVIEW
Lukas Schwingshackl, Carolina Schwedhelm, Cecilia Galbete, Georg Hoffmann
The aim of the present systematic review and meta-analysis was to gain further insight into the effects of adherence to Mediterranean Diet (MedD) on risk of overall cancer mortality, risk of different types of cancer, and cancer mortality and recurrence risk in cancer survivors. Literature search was performed using the electronic databases PubMed, and Scopus until 25 August 2017. We included randomized trials (RCTs), cohort (for specific tumors only incidence cases were used) studies, and case-control studies...
September 26, 2017: Nutrients
https://www.readbyqxmd.com/read/28953950/shenqi-fuzheng-injection-combined-with-chemotherapy-in-the-treatment-of-colorectal-cancer-a-meta-analysis
#18
Rongzhong Xu, Liubing Lin, Yong Li, Yan Li
OBJECTIVE: This study aims to investigate cellular immunity and clinical efficacy of ShenQi FuZheng Injection (SFI) in the associated chemotherapy of colorectal cancer (CRC). METHODS: PubMed, Cochrane Library, EMBASE, China National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Full-text Database (VIP), WanFang Database and Chinese Biomedical Literature Database (CBM) searches were undertaken to identify randomized controlled trials of SFI plus chemotherapy versus chemotherapy alone in CRC patients...
2017: PloS One
https://www.readbyqxmd.com/read/28953134/national-trends-in-extended-procedures-for-ovarian-cancer-debulking-surgery
#19
Nathaniel L Jones, Ling Chen, Sudeshna Chatterjee, Ana I Tergas, William M Burke, June Y Hou, Cande V Ananth, Alfred I Neugut, Dawn L Hershman, Jason D Wright
OBJECTIVE: Primary cytoreduction for ovarian cancer often requires extended radical procedures and is associated with significant morbidity. In 2010, neoadjuvant chemotherapy was shown to have similar survival to primary cytoreduction but with less need for radical surgery. We hypothesized that the increased use of neoadjuvant chemotherapy would decrease the use of radical cytoreductive procedures and thus examined trends in the performance of radical cytoreductive procedures. METHODS: We used the Nationwide Inpatient Sample to determine the annual number of extended procedures (colon, small intestine, liver, diaphragm, spleen, and gastric resection, ileostomy, colostomy) performed in women undergoing surgery for ovarian cancer from 1998 to 2013...
September 22, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28943046/radical-radiation-therapy-for-oligometastatic-breast-cancer-results-of-a-prospective-phase-ii-trial
#20
Marco Trovo, Carlo Furlan, Jerry Polesel, Francesco Fiorica, Stefano Arcangeli, Niccolò Giaj-Levra, Filippo Alongi, Alessandro Del Conte, Loredana Militello, Elena Muraro, Debora Martorelli, Simon Spazzapan, Massimiliano Berretta
BACKGROUND AND PURPOSE: We conducted a prospective phase II multicentric trial to determine if radical radiation therapy to all metastatic sites might improve the progression-free survival (PFS) in oligometastatic breast cancer patients. Secondary endpoints were local control (LC), overall survival (OS) and toxicity. METHODS AND MATERIALS: Inclusion criteria were the following: oligometastatic breast cancer with ≤5 metastatic sites, FDG-PET/CT staging, no brain metastases, primary tumor controlled...
September 21, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
keyword
keyword
28809
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"